ANBL1531 for High-Risk Neuroblastoma - Clinical Trial

We are doing this study to find out if we can improve the treatment for patients with high-risk neuroblastoma by adding the study drug 131I-MIBG (131I-metaiodobenzylguanidine) or the study drug crizotinib to the standard treatment.

Newly Diagnosed High-Risk Neuroblastoma

Children and Adults with Neuroblastoma who:
- Are 1 year old and less than 30 years old
- Are able to tolerate peripheral blood stem cell collection

If you choose to be in this study, you will:
- Be randomized (like drawing numbers out of a hat) to get either:
-- Group 1: Standard of care treatment
-- Group 2: Study drug 131I-MIBG and standard of care treatment
-- Group 3: Study drug 131I-MIBG and one stem cell transplant and standard of care chemotherapy
-- Group 4: Standard of care treatment
-- Group 5: Study drug Crizotinib plus standard of care treatment
- Have a scan and have tissue taken from your tumor sent for a test to see if it contains a specific gene
- Have standard treatment called induction therapy